NCT05145764View on ClinicalTrials.gov

Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 30, 2022

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
SuvorexantPlaceboOpioid Use Disorder
Interventions
DRUG

Suvorexant

Encapsulated suvorexant (matched for color, weight, and size)

DRUG

Placebo

Encapsulated placebo (matched for color, weight, and size)

Trial Locations (1)

21224

RECRUITING

Johns Hopkins Bayview Medical Center, Baltimore

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Johns Hopkins University

OTHER